Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn’s disease. National data from Hungary

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

(2011) Matthias Jürgens et al.   Clinical Gastroenterology and Hepatology

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

(2010) R. PANACCIONE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohnʼs disease, while smoking decreases the risk of colectomy in ulcerative colitis

(2010) Tamas Szamosi et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

W1275 Long-Term Durability of Response to Adalimumab Treatment in Crohn's Disease

(2010) Maria Chaparro et al.   GASTROENTEROLOGY

T1239 Adalimumab Treatment Results in Deep Remission for Patients With Moderate to Severe Ileocolonic Crohn's Disease: Results From EXTEND

(2010) Jean-Frédéric Colombel et al.   GASTROENTEROLOGY

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy

(2010) H. Sokol et al.   GUT

Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohnʼs disease

(2010) Peter Laszlo Lakatos et al.   INFLAMMATORY BOWEL DISEASES

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

(2010) Gert Van Assche et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Is the disease course predictable in inflammatory bowel diseases?

(2010) Peter Laszlo Lakatos   WORLD JOURNAL OF GASTROENTEROLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

(2009) Filip Baert et al.   GASTROENTEROLOGY

Adalimumab for the treatment of fistulas in patients with Crohn's disease

(2009) J-F Colombel et al.   GUT

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease

(2009) Fabian Schnitzler et al.   INFLAMMATORY BOWEL DISEASES

10 - Patterns and predictors of dosage increase in patients treated with adalimumab for Crohn's disease in the United States

(2009) E.V. Loftus et al.   Journal of Crohns & Colitis

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

(2008) Gert Van Assche et al.   GASTROENTEROLOGY

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT